NO831517L - Fremgangsmaate for fremstilling av benzotiazolforbindelser - Google Patents
Fremgangsmaate for fremstilling av benzotiazolforbindelserInfo
- Publication number
- NO831517L NO831517L NO831517A NO831517A NO831517L NO 831517 L NO831517 L NO 831517L NO 831517 A NO831517 A NO 831517A NO 831517 A NO831517 A NO 831517A NO 831517 L NO831517 L NO 831517L
- Authority
- NO
- Norway
- Prior art keywords
- triazino
- benzothiazole
- amino
- compound
- formula
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 113
- 238000000034 method Methods 0.000 title claims abstract description 29
- 150000003839 salts Chemical class 0.000 claims abstract description 19
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 18
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 17
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 14
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 12
- 150000002367 halogens Chemical class 0.000 claims abstract description 12
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 6
- 125000002071 phenylalkoxy group Chemical group 0.000 claims abstract description 6
- 125000004423 acyloxy group Chemical group 0.000 claims abstract description 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 3
- 238000004519 manufacturing process Methods 0.000 claims abstract description 3
- 239000001257 hydrogen Substances 0.000 claims description 24
- 229910052739 hydrogen Inorganic materials 0.000 claims description 24
- -1 benzyloxyphenyl Chemical group 0.000 claims description 22
- 150000002431 hydrogen Chemical class 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 230000010933 acylation Effects 0.000 claims description 4
- 238000005917 acylation reaction Methods 0.000 claims description 4
- 229910052799 carbon Inorganic materials 0.000 claims description 4
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims description 4
- PCMWWWOZYVQEOJ-UHFFFAOYSA-N 8-methoxy-2-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-4-amine Chemical compound C=1C(OC)=CC=C(N2C(=N)N=3)C=1SC2=NC=3NC1=CC=CC=C1 PCMWWWOZYVQEOJ-UHFFFAOYSA-N 0.000 claims description 3
- MGSUAUVCDPKWRX-UHFFFAOYSA-N 8-methoxy-4-methylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound NC1=NC(=NC)N2C3=CC=C(OC)C=C3SC2=N1 MGSUAUVCDPKWRX-UHFFFAOYSA-N 0.000 claims description 3
- XNTOZBMKBYPUBH-UHFFFAOYSA-N 8-methoxy-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=CC=C1 XNTOZBMKBYPUBH-UHFFFAOYSA-N 0.000 claims description 3
- IMMDAZOIWSLUOK-UHFFFAOYSA-N 8-methoxy-n-phenyl-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N2C(=NC=3C=CC=CC=3)N=3)C=1SC2=NC=3NC1=CC=CC=C1 IMMDAZOIWSLUOK-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 125000004432 carbon atom Chemical group C* 0.000 claims description 3
- 238000003776 cleavage reaction Methods 0.000 claims description 3
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 230000007017 scission Effects 0.000 claims description 3
- VQEMLZKWBBKWBW-UHFFFAOYSA-N 4-cyclohexylimino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1CCCCC1 VQEMLZKWBBKWBW-UHFFFAOYSA-N 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000004464 hydroxyphenyl group Chemical group 0.000 claims description 2
- VUVIHJNCAJWTSA-UHFFFAOYSA-N n-(4-anilino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-ylidene)acetamide Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(NC(C)=O)=NC2=NC1=CC=CC=C1 VUVIHJNCAJWTSA-UHFFFAOYSA-N 0.000 claims description 2
- 125000003944 tolyl group Chemical group 0.000 claims description 2
- SHIBOJMAXWSODF-UHFFFAOYSA-N 10-imino-8-methoxy-4-(4-methoxyphenyl)-4H-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound NC=1N=C2S(C3=C(N2C(N=1)C1=CC=C(C=C1)OC)C=CC(=C3)OC)=N SHIBOJMAXWSODF-UHFFFAOYSA-N 0.000 claims 1
- MLJNEGPZYMTAEB-UHFFFAOYSA-N 2-amino-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-8-ol Chemical compound N1=C(N)N=C2SC3=CC(O)=CC=C3N2C1=NC1=CC=CC=C1 MLJNEGPZYMTAEB-UHFFFAOYSA-N 0.000 claims 1
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 claims 1
- UJOVFVWADYJIOX-UHFFFAOYSA-N 4-(2,6-dichlorophenyl)imino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=C(Cl)C=CC=C1Cl UJOVFVWADYJIOX-UHFFFAOYSA-N 0.000 claims 1
- BSOZFZTXLYBNBD-UHFFFAOYSA-N 4-(3,4-dichlorophenyl)imino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=C(Cl)C(Cl)=C1 BSOZFZTXLYBNBD-UHFFFAOYSA-N 0.000 claims 1
- PHZANCAEUMFALN-UHFFFAOYSA-N 4-(4-chlorophenyl)imino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=C(Cl)C=C1 PHZANCAEUMFALN-UHFFFAOYSA-N 0.000 claims 1
- LVQYCPNUXDAELN-UHFFFAOYSA-N 4-[(2-amino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-4-ylidene)amino]benzoic acid Chemical compound COC1=CC=C2N3C(SC2=C1)=NC(N)=NC3=NC1=CC=C(C=C1)C(O)=O LVQYCPNUXDAELN-UHFFFAOYSA-N 0.000 claims 1
- XJMVAHITRKWIPJ-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]imino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=C(N(C)C)C=C1 XJMVAHITRKWIPJ-UHFFFAOYSA-N 0.000 claims 1
- GRMMOVVXSZWFOJ-UHFFFAOYSA-N 4-[4-[2-(diethylamino)ethoxy]phenyl]imino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C1=CC(OCCN(CC)CC)=CC=C1N=C1N2C3=CC=C(OC)C=C3SC2=NC(N)=N1 GRMMOVVXSZWFOJ-UHFFFAOYSA-N 0.000 claims 1
- YHVUNKRIJNUUQQ-UHFFFAOYSA-N 4-benzylimino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NCC1=CC=CC=C1 YHVUNKRIJNUUQQ-UHFFFAOYSA-N 0.000 claims 1
- MDGACZNIUWOYJT-UHFFFAOYSA-N 4-n-phenyl-[1,3,5]triazino[1,2-a]benzimidazole-2,4-diamine Chemical compound N1=C(N)N=C2NC3=CC=CC=C3N2C1=NC1=CC=CC=C1 MDGACZNIUWOYJT-UHFFFAOYSA-N 0.000 claims 1
- OBVZZSMBEUGPCC-UHFFFAOYSA-N 4-phenylimino-8-propan-2-yloxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC(C)C)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=CC=C1 OBVZZSMBEUGPCC-UHFFFAOYSA-N 0.000 claims 1
- RNMGGUBWJPTGAZ-UHFFFAOYSA-N 4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound N1=C(N)N=C2SC3=CC=CC=C3N2C1=NC1=CC=CC=C1 RNMGGUBWJPTGAZ-UHFFFAOYSA-N 0.000 claims 1
- BTFDZWOPAJDRNO-UHFFFAOYSA-N 4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzoxazol-2-amine Chemical compound N1=C(N)N=C2OC3=CC=CC=C3N2C1=NC1=CC=CC=C1 BTFDZWOPAJDRNO-UHFFFAOYSA-N 0.000 claims 1
- ZJBLQYMELNPSLF-UHFFFAOYSA-N 4-tert-butylimino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound NC1=NC(=NC(C)(C)C)N2C3=CC=C(OC)C=C3SC2=N1 ZJBLQYMELNPSLF-UHFFFAOYSA-N 0.000 claims 1
- OVZUUBCZWWJMHJ-UHFFFAOYSA-N 7,8-dimethyl-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound N12C=3C=C(C)C(C)=CC=3SC2=NC(N)=NC1=NC1=CC=CC=C1 OVZUUBCZWWJMHJ-UHFFFAOYSA-N 0.000 claims 1
- GYVUAEFCULMFNP-UHFFFAOYSA-N 8-chloro-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound N1=C(N)N=C2SC3=CC(Cl)=CC=C3N2C1=NC1=CC=CC=C1 GYVUAEFCULMFNP-UHFFFAOYSA-N 0.000 claims 1
- CYBMXOKNQXRQQG-UHFFFAOYSA-N 8-methoxy-4-(2-phenylmethoxyphenyl)imino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=CC=C1OCC1=CC=CC=C1 CYBMXOKNQXRQQG-UHFFFAOYSA-N 0.000 claims 1
- HGCGBIGIDLUCRI-UHFFFAOYSA-N 8-methoxy-4-(4-methylphenyl)imino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=C(C)C=C1 HGCGBIGIDLUCRI-UHFFFAOYSA-N 0.000 claims 1
- PPMILQMAHHIIMD-UHFFFAOYSA-N 8-methoxy-4-(4-nitrophenyl)imino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=C([N+]([O-])=O)C=C1 PPMILQMAHHIIMD-UHFFFAOYSA-N 0.000 claims 1
- FCDJBCLKLOVCFE-UHFFFAOYSA-N 8-methyl-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound C=1C(C)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=CC=C1 FCDJBCLKLOVCFE-UHFFFAOYSA-N 0.000 claims 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- PRXAKGDDRKQSAF-UHFFFAOYSA-N ethyl 4-[(2-amino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-4-ylidene)amino]benzoate Chemical compound C1=CC(C(=O)OCC)=CC=C1N=C1N2C3=CC=C(OC)C=C3SC2=NC(N)=N1 PRXAKGDDRKQSAF-UHFFFAOYSA-N 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000000203 mixture Substances 0.000 abstract description 29
- 239000003814 drug Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 34
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 33
- 239000000243 solution Substances 0.000 description 30
- 239000000047 product Substances 0.000 description 28
- 239000007787 solid Substances 0.000 description 21
- 238000006243 chemical reaction Methods 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 17
- 238000001819 mass spectrum Methods 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- 239000013078 crystal Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- 238000001953 recrystallisation Methods 0.000 description 11
- 239000000706 filtrate Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000003921 oil Substances 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 6
- 229960002523 mercuric chloride Drugs 0.000 description 6
- LWJROJCJINYWOX-UHFFFAOYSA-L mercury dichloride Chemical compound Cl[Hg]Cl LWJROJCJINYWOX-UHFFFAOYSA-L 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000007858 starting material Substances 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 239000000460 chlorine Substances 0.000 description 5
- 239000012312 sodium hydride Substances 0.000 description 5
- 229910000104 sodium hydride Inorganic materials 0.000 description 5
- 241000700198 Cavia Species 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- IOJUPLGTWVMSFF-UHFFFAOYSA-N benzothiazole Chemical compound C1=CC=C2SC=NC2=C1 IOJUPLGTWVMSFF-UHFFFAOYSA-N 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000009835 boiling Methods 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000012074 organic phase Substances 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 230000000699 topical effect Effects 0.000 description 4
- SJHPCNCNNSSLPL-CSKARUKUSA-N (4e)-4-(ethoxymethylidene)-2-phenyl-1,3-oxazol-5-one Chemical compound O1C(=O)C(=C/OCC)\N=C1C1=CC=CC=C1 SJHPCNCNNSSLPL-CSKARUKUSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
- KZHGPDSVHSDCMX-UHFFFAOYSA-N 6-methoxy-1,3-benzothiazol-2-amine Chemical compound COC1=CC=C2N=C(N)SC2=C1 KZHGPDSVHSDCMX-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 3
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 238000002054 transplantation Methods 0.000 description 3
- YQZXJDJUNGXIPX-UHFFFAOYSA-N 1-cyano-3-phenylthiourea Chemical compound N#CNC(=S)NC1=CC=CC=C1 YQZXJDJUNGXIPX-UHFFFAOYSA-N 0.000 description 2
- JQHGAVRMSKHICJ-UHFFFAOYSA-N 2-(6-methoxy-1,3-benzothiazol-2-yl)guanidine Chemical compound COC1=CC=C2N=C(NC(N)=N)SC2=C1 JQHGAVRMSKHICJ-UHFFFAOYSA-N 0.000 description 2
- HPLHJODTTNDXBP-UHFFFAOYSA-N 4-n-phenyl-[1,3,5]triazino[1,2-a]benzimidazole-2,4-diamine;hydrochloride Chemical compound Cl.N1=C(N)N=C2NC3=CC=CC=C3N2C1=NC1=CC=CC=C1 HPLHJODTTNDXBP-UHFFFAOYSA-N 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- LGDSHSYDSCRFAB-UHFFFAOYSA-N Methyl isothiocyanate Chemical compound CN=C=S LGDSHSYDSCRFAB-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229960000583 acetic acid Drugs 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 238000011316 allogeneic transplantation Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 208000010247 contact dermatitis Diseases 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- QKFJKGMPGYROCL-UHFFFAOYSA-N phenyl isothiocyanate Chemical compound S=C=NC1=CC=CC=C1 QKFJKGMPGYROCL-UHFFFAOYSA-N 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 238000007363 ring formation reaction Methods 0.000 description 2
- 230000008313 sensitization Effects 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- NYBWUHOMYZZKOR-UHFFFAOYSA-N tes-adt Chemical class C1=C2C(C#C[Si](CC)(CC)CC)=C(C=C3C(SC=C3)=C3)C3=C(C#C[Si](CC)(CC)CC)C2=CC2=C1SC=C2 NYBWUHOMYZZKOR-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 2
- WFVAUHDMXMWXHI-UHFFFAOYSA-N (6-methoxy-1,3-benzothiazol-2-yl)thiourea Chemical compound COC1=CC=C2N=C(NC(N)=S)SC2=C1 WFVAUHDMXMWXHI-UHFFFAOYSA-N 0.000 description 1
- TTWWZVGVBRPHLE-UHFFFAOYSA-N 1,1-dichloro-n-phenylmethanimine Chemical compound ClC(Cl)=NC1=CC=CC=C1 TTWWZVGVBRPHLE-UHFFFAOYSA-N 0.000 description 1
- GLCIGSUVWSYVOK-UHFFFAOYSA-N 1-cyano-2-(6-methoxy-1,3-benzothiazol-2-yl)-3-phenylguanidine Chemical compound S1C2=CC(OC)=CC=C2N=C1N=C(NC#N)NC1=CC=CC=C1 GLCIGSUVWSYVOK-UHFFFAOYSA-N 0.000 description 1
- QMHWARSFUCGBJK-UHFFFAOYSA-N 2-(1,3-benzothiazol-2-yl)guanidine Chemical compound C1=CC=C2SC(N=C(N)N)=NC2=C1 QMHWARSFUCGBJK-UHFFFAOYSA-N 0.000 description 1
- JWYUFVNJZUSCSM-UHFFFAOYSA-N 2-aminobenzimidazole Chemical compound C1=CC=C2NC(N)=NC2=C1 JWYUFVNJZUSCSM-UHFFFAOYSA-N 0.000 description 1
- UHGULLIUJBCTEF-UHFFFAOYSA-N 2-aminobenzothiazole Chemical compound C1=CC=C2SC(N)=NC2=C1 UHGULLIUJBCTEF-UHFFFAOYSA-N 0.000 description 1
- VRVRGVPWCUEOGV-UHFFFAOYSA-N 2-aminothiophenol Chemical compound NC1=CC=CC=C1S VRVRGVPWCUEOGV-UHFFFAOYSA-N 0.000 description 1
- QRJZGVVKGFIGLI-UHFFFAOYSA-N 2-phenylguanidine Chemical compound NC(=N)NC1=CC=CC=C1 QRJZGVVKGFIGLI-UHFFFAOYSA-N 0.000 description 1
- SRRLBWYVQNVAGV-UHFFFAOYSA-N 4-[(2-amino-8-methoxy-[1,3,5]triazino[2,1-b][1,3]benzothiazol-4-ylidene)amino]phenol Chemical compound C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=C(O)C=C1 SRRLBWYVQNVAGV-UHFFFAOYSA-N 0.000 description 1
- IXNNVZAZSOBUOD-UHFFFAOYSA-N 4-imino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine Chemical compound S1C2=CC=CC=C2N2C1=NC(N)=NC2=N IXNNVZAZSOBUOD-UHFFFAOYSA-N 0.000 description 1
- HQULYFAKUZDRPB-UHFFFAOYSA-N 6-bromo-2-[4-(trifluoromethoxy)phenoxy]-1,3-benzothiazole Chemical compound BrC1=CC2=C(N=C(S2)OC2=CC=C(C=C2)OC(F)(F)F)C=C1 HQULYFAKUZDRPB-UHFFFAOYSA-N 0.000 description 1
- UDDOOOHJKUKMCD-UHFFFAOYSA-N 8-methoxy-4-phenylimino-[1,3,5]triazino[2,1-b][1,3]benzothiazol-2-amine;hydrochloride Chemical compound Cl.C=1C(OC)=CC=C(N23)C=1SC3=NC(N)=NC2=NC1=CC=CC=C1 UDDOOOHJKUKMCD-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000026872 Addison Disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 238000011749 CBA mouse Methods 0.000 description 1
- JGLMVXWAHNTPRF-CMDGGOBGSA-N CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O Chemical compound CCN1N=C(C)C=C1C(=O)NC1=NC2=CC(=CC(OC)=C2N1C\C=C\CN1C(NC(=O)C2=CC(C)=NN2CC)=NC2=CC(=CC(OCCCN3CCOCC3)=C12)C(N)=O)C(N)=O JGLMVXWAHNTPRF-CMDGGOBGSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010014198 Eczema infantile Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- KQJQICVXLJTWQD-UHFFFAOYSA-N N-Methylthiourea Chemical compound CNC(N)=S KQJQICVXLJTWQD-UHFFFAOYSA-N 0.000 description 1
- 201000009053 Neurodermatitis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000033464 Reiter syndrome Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 231100000354 acute hepatitis Toxicity 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000001449 anionic compounds Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 1
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 125000005843 halogen group Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229910000037 hydrogen sulfide Inorganic materials 0.000 description 1
- 230000008105 immune reaction Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 229910001412 inorganic anion Inorganic materials 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- PELJISAVHGXLAL-UHFFFAOYSA-N iodomethyl 2,2-dimethylpropanoate Chemical compound CC(C)(C)C(=O)OCI PELJISAVHGXLAL-UHFFFAOYSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036244 malformation Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002730 mercury Chemical class 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- YPYOGESDTBGZIQ-UHFFFAOYSA-N n,n-diethyl-2-(4-isothiocyanatophenoxy)ethanamine Chemical compound CCN(CC)CCOC1=CC=C(N=C=S)C=C1 YPYOGESDTBGZIQ-UHFFFAOYSA-N 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 201000005737 orchitis Diseases 0.000 description 1
- 150000002891 organic anions Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003973 paint Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229940117953 phenylisothiocyanate Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 208000002574 reactive arthritis Diseases 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000003797 solvolysis reaction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000003419 tautomerization reaction Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Transplantation (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Sorting Of Articles (AREA)
- Body Structure For Vehicles (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8212654 | 1982-04-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO831517L true NO831517L (no) | 1983-10-31 |
Family
ID=10530109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO831517A NO831517L (no) | 1982-04-30 | 1983-04-29 | Fremgangsmaate for fremstilling av benzotiazolforbindelser |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US4499269A (da) |
| EP (1) | EP0093515B1 (da) |
| JP (1) | JPS58194889A (da) |
| AT (1) | ATE25087T1 (da) |
| AU (1) | AU552775B2 (da) |
| DE (1) | DE3369322D1 (da) |
| DK (1) | DK182183A (da) |
| FI (1) | FI831289L (da) |
| NO (1) | NO831517L (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7291616B2 (en) * | 2001-10-31 | 2007-11-06 | Cell Therapeutics, Inc. | Aryl triazines as LPAAT-β inhibitors and uses thereof |
| US7419984B2 (en) * | 2002-10-17 | 2008-09-02 | Cell Therapeutics, Inc. | Pyrimidines and uses thereof |
| US6875781B2 (en) * | 2003-04-04 | 2005-04-05 | Cell Therapeutics, Inc. | Pyridines and uses thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3309366A (en) * | 1963-04-05 | 1967-03-14 | Geigy Ag J R | Imidazole(1, 2)-s-triazines |
-
1983
- 1983-04-08 DE DE8383301978T patent/DE3369322D1/de not_active Expired
- 1983-04-08 EP EP83301978A patent/EP0093515B1/en not_active Expired
- 1983-04-08 AT AT83301978T patent/ATE25087T1/de not_active IP Right Cessation
- 1983-04-18 FI FI831289A patent/FI831289L/fi not_active Application Discontinuation
- 1983-04-20 US US06/486,795 patent/US4499269A/en not_active Expired - Fee Related
- 1983-04-25 DK DK182183A patent/DK182183A/da not_active Application Discontinuation
- 1983-04-26 JP JP58072329A patent/JPS58194889A/ja active Pending
- 1983-04-26 AU AU13938/83A patent/AU552775B2/en not_active Ceased
- 1983-04-29 NO NO831517A patent/NO831517L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FI831289A0 (fi) | 1983-04-18 |
| US4499269A (en) | 1985-02-12 |
| AU1393883A (en) | 1983-11-03 |
| ATE25087T1 (de) | 1987-02-15 |
| JPS58194889A (ja) | 1983-11-12 |
| FI831289L (fi) | 1983-10-31 |
| DK182183D0 (da) | 1983-04-25 |
| DK182183A (da) | 1983-10-31 |
| AU552775B2 (en) | 1986-06-19 |
| EP0093515B1 (en) | 1987-01-21 |
| DE3369322D1 (en) | 1987-02-26 |
| EP0093515A1 (en) | 1983-11-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2172315C1 (ru) | Способ получения рацемических или оптически активных метил(2-галогенофенил)(6,7-дигидро-4н-тиено[3,2-с]пиридин-5-ил)ацетатов или их солей | |
| BR112014030091B1 (pt) | processos para produzir certos 2-(piridina-3-il)tiazóis | |
| CA2283718A1 (en) | Crystalline amine salt of cefdinir | |
| SE416810B (sv) | Forfarande for framstellning av xantinderivat med antiallergisk aktivitet | |
| Bell et al. | Synthesis of substituted 3‐amino [6, 5‐b] triazinoindoles | |
| HU225504B1 (en) | Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them | |
| CZ323094A3 (en) | Branched amino derivatives of thiazole, process of their preparation and pharmaceutical compositions containing thereof | |
| NO762661L (da) | ||
| IE910853A1 (en) | 2,4-pyrimidinedione derivatives and pharmaceutical compositions containing them | |
| SE446267B (sv) | Nya kinolylguanidinderivat, forfaranden for framstellning derav samt farmaceutiska kompositioner innehallande nemnda derivat | |
| NO831517L (no) | Fremgangsmaate for fremstilling av benzotiazolforbindelser | |
| US3847934A (en) | 7-(imidazolinyl-(2)-amino)-indazoles | |
| NO174200B (no) | Analogifremgangsm}te for fremstilling av terapeutisk aktive 2-imino-6-polyfluoralkoksybenzotiazol-forbindelser | |
| US2467895A (en) | Piperazine derivatives and method of preparing the same | |
| AU2010305397B2 (en) | Method for the synthesis of 2-thiohistidine and the like | |
| PL109995B1 (en) | Method of producing derivatives of 4-/n-acetylo/aminotetrahydro-1,3,5-triazynodione-2,6 | |
| SE449746B (sv) | Forfarande for framstellning av 4-metyl-5-alkyl-tioimidazoler | |
| US4179460A (en) | Derivatives of R,S-[X2-(2-hydroxyethylamino)-1-phenyl]-ethylamine, and process | |
| US4254259A (en) | 2-Amino-5-ethylovalyl-6H-1,3,4-thiadiazine oxime | |
| NO883263L (no) | Fremgangsmaate for fremstilling av terapeutisk aktive benzimidazol-derivater. | |
| KR100682292B1 (ko) | Ｎ,Ｎ-이치환된-ｐ-페닐렌디아민의 개선된 합성 방법 | |
| CA1085399A (en) | Conversion of trans-to cis-n,n-dimethyl-9- 3-(4- methyl-1-piperazinyl)propylidene thioxanthene-2- sulfonamide and recovery of the cis-isomer | |
| CA2022903A1 (en) | Imidazole derivatives, process for the preparation of the same and antiulcer agents containing the same | |
| JPS62263160A (ja) | 置換アントラ〔１，９−ｃｄ〕ピラゾ−ル−６（２Ｈ）−オン類の製造方法 | |
| JPS62212378A (ja) | ジアリ−ルスルフイド誘導体 |